What is Artelo Biosciences, Inc. (ARTL)?

Artelo Biosciences, Inc. (ARTL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ARTL?

The current price of ARTL is $2.33. Prices are updated in real time on Stocks360.

What is ARTL's price-to-earnings (PE) ratio?

ARTL's trailing twelve-month PE ratio is -0.03, based on current price and earnings per share data available on Stocks360.

What is ARTL's market capitalization?

ARTL's market capitalization is $8,121,308.00, placing it in the small-cap tier.

Artelo Biosciences, Inc. (ARTL)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$2.33

Market Cap

$8.12M

PE (TTM)

-0.03

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.07

Day Range

$2.24 – $2.42

52-wk Range

$2.05 – $179.19

Avg Volume

N/A

Volume

41.74K

Artelo Biosciences, Inc. (ARTL) is a publicly traded company in the Healthcare sector. Latest price: $2.33. Market cap $8.12M. Trailing PE -0.03. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $31.77 2026-10-28 · $2.33 (-92.67%)

Earnings

Most Recent

Aug 12, 2026

EPS $-8.01 vs est. $-6.48

Missed by $1.53

Next Earnings

Nov 17, 2026

EPS estimate $-7.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.03×
P/S (TTM)	0.00×
P/B	0.14×
PEG	0.00×
P/FCF (TTM)	-0.64×
EV / EBITDA	-0.33×
EV / Sales	0.00×
Earnings Yield	-1804.71%
Free Cash Flow Yield	-155.55%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$3.97M
Net Income (TTM)	-$146.57M
Free Cash Flow (TTM)	-$12.02M
Net Debt	-$4.15M
Working Capital	$2.92M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-519.09%
Return on Invested Capital	-219.36%